Truxima Hits 20% Share For Teva
Rheumatoid Arthritis Indication Helps Rituximab Biosimilar Gain Ground In US
Teva says the Truxima rituximab biosimilar it sells in the US in partnership with Celltrion has captured a fifth of the market a year after launch, driven in part by its exclusive rheumatoid arthritis indication.
You may also be interested in...
Shanghai Henlius Biotech has taken its groundbreaking Chinese rituximab biosimilar a step closer to securing a key rheumatoid arthritis indication.
With a couple of major partnerships and a stable of internal projects, Teva expects to play a role in the “majority of meaningful US biosimilar launches in the next five-to-eight years,” executive vice-president for North America commercial Brendan O’Grady told Generics Bulletin in an exclusive interview.
South Korea’s Celltrion saw a double-digit jump in sales and operating profit in 2020 based on continued growth for its leading biosimilars. Meanwhile, the company is pursuing its strategy of developing at least one biosimilar annually.